Azithromycin proving its worth

Article

Azithromycin is just as effective and safe as tobramycin for the treatment of purulent bacterial conjunctivitis, according to a report published in the April issue of the British Journal of Ophthalmology.

Azithromycin is just as effective and safe as tobramycin for the treatment of purulent bacterial conjunctivitis, according to a report published in the April issue of the British Journal of Ophthalmology.

Isabelle Cochereau from CHU d'Angers, France and colleagues from Tunisia, Morocco, Romania and India conducted a multicentre, randomized, investigator-masked study, which included 1,043 children and adults with purulent bacterial conjunctivits. Patients were randomized to receive either azithromycin 1.5% twice-daily for three days or tobramycin 0.3%, one drop every two hours for two days and then four times daily for five days. Clinical signs were evaluated and cultures obtained at baseline and three and nine days following the commencement of treatment.

Among 471 patients with baseline positivity, 87.8% of the azithromycin group and 89.4% of the tobramycin group were clinically cured by the final examination. Clinical cure was, however, significantly higher with azithromycin at day three.

It was concluded that azithromycin is just as effective as tobramycin for treating purulent bacterial conjunctivitis. Additionally, it only requires a twice-daily dosing regimen, which should help increase patient compliance.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.